This message was sent to ##Email##
To advertise in this publication please click here
|
|
|
.FITNESS & WELLNESS
Exercise after COVID-19? Take it slow
The New York Times
Jordan D. Metzl, M.D. writes: "For the past 20 years, when patients asked me about exercising while recovering from a viral illness like the flu, I gave them the same advice: Listen to your body. If exercise usually makes you feel better, go for it.
COVID-19 has changed my advice."
|
|
A comprehensive look at the metabolic impact of exercise
Technology Networks
Short bursts of physical exercise induce changes in the body’s levels of metabolites that correlate to, and may help gauge, an individual’s cardiometabolic, cardiovascular and long-term health, a study by Massachusetts General Hospital has found. In a paper published in Circulation, the research team describes how approximately 12 minutes of acute cardiopulmonary exercise impacted more than 80% of circulating metabolites.
|
|
Elliptical vs. running: Which one gives you the most effective cardio workout?
Well + Good
Grab your mask and walk into any gym and you’re bound to see two cardio machines getting a lot of use: the elliptical and the treadmill. At some gyms, both pieces of workout equipment are so popular that there’s a sign-up list for each. But it begs the question: In the head-to-head battle of elliptical vs. running, which is the most effective workout?
|
|
.DIET & NUTRITION
Vegan diets raise concerns for iodine deficiency
Medical News Today
There are many benefits to a vegan diet, including a lower risk of heart disease, cancer and type 2 diabetes.
However, a growing concern is the lack of dietary nutrients that are mainly present in animal foods. Two important nutrients are vitamin B12 and iodine.
|
|
The Mediterranean diet is a healthy eating plan — but it's far from universal
Well + Good
There are some eating plans that have been controversial from the get-go, like the ketogenic diet, Whole30 and intermittent fasting. But the Mediterranean diet — an eating plan that advocates for lean proteins, whole grains, seafood and plenty of vegetables along with the occasional glass of wine — has long been the least problematic of any eating plan, quick to be endorsed by doctors, dietitians and other healthy eating experts.
|
|
.RESEARCH & DEVELOPMENT
Can exercise decrease mortality risk in patients with depression?
Psychiatric Times
"People suffering from depression die, on average, 10 years earlier than non-depressed individuals.” You must have heard this while attending a conference, reading a journal, or simply in a discussion with a colleague. It has little to do with the risk of suicide: we are mainly talking about death due to physical causes and, in particular, cardiovascular causes.
|
|
Chair-based exercise is safe and effective for nursing home residents: Study
McKnight's Long-Term Care News
Task-specific, chair-based exercise is safe and effective for nursing home residents, according to an analysis of recent studies.
The authors vetted 10 studies involving a total of 551 people with a mean age of 79. The exercise programs differed in size and training type. They included multicomponent exercises and varying exercise frequency, including length of session and program.
|
|
Study: Diet trends to see 4 billion people overweight by 2050
Eyewitness News
More than four billion people could be overweight by 2050, with 1.5 billion of them obese, if the current global dietary trend towards processed foods continues, a first-of-its-kind study predicted Wednesday.
Warning of a health and environmental crisis of "mind-blowing magnitude", experts from the Potsdam Institute for Climate Impact Research said that global food demand would leap 50% by mid-century, pushing past Earth's capacity to sustain nature.
|
|
.VITAMINS & PHARMACEUTICALS
Multivitamins don't provide many health benefits, researchers say
Healthline
People in the U.S. reportedly spend more than $30 billion per year on vitamins and supplements.
About 3 in 4 Americans takes a dietary supplement every day.
However, there’s scant evidence that multivitamins or mineral supplements have any positive impact on health, except for people with known vitamin or mineral deficiencies.
|
|
Can supplements boost your immunity this winter?
WebMD
With COVID-19 cases on the rise and cold and flu season well underway, people are seeking ways to boost their disease defenses. Sales of immune health supplements are projected to grow from $16 billion in 2019 to $29 billion by 2027, spurred in part by the pandemic, according to research from Fortune Business Insights.
|
|
Adding vitamin B3 to your diet may offer UV protection on those long runs
MSN
Even in the winter, dermatologists recommend applying sunscreen if you’re going to be outside for extended periods of time, like when you’re running, cycling or doing other outdoor activities. As it turns out, adding some key vitamins to your diet may also protect you from UV exposure, a recent study suggests.
|
|
.NAMCP UPDATES
| | | | | |
| LivaNova PLC, a market-leading medical technology and innovation company, today announced the publication of a new study in the International Journal of Bipolar Disorders that showed adding Vagus Nerve Stimulation Therapy (VNS Therapy®) to treatment as usual (TAU) significantly improves outcomes in patients with treatment-resistant bipolar depression (TRBD). The study examined patients from a five-year prospective registry and found 63% of TRBD patients treated with adjunctive VNS Therapy in addition to TAU had a significant reduction in depressive symptoms, as measured by a 50% or greater reduction in the Montgomery–Åsberg Depression Rating Scale (MADRS), compared with 39% of patients in the TAU alone group. Click here to view the entire press release. Click here to view the entire press release.
|
| Additionally, LivaNova PLC announced a publication in Contemporary Clinical Trials, which details the design for “A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression” or the RECOVER clinical study. RECOVER is currently under way as part of a Coverage with Evidence Development framework of the U.S. Centers for Medicare & Medicaid Services’ (CMS) National Coverage Determination process. Click here to view the entire press release.
|
| In late 2018, the National Association of Managed Care Physicians (NAMCP) decided to create the Value Based Care Council (VBCC). The VBCC mission supports empowering medical directors with information and resources to assist them in making value based decisions that support achieving the Triple AIM of improved outcomes and the patient experience while reducing overall costs. The goal is to improve the integration of cost, quality, and access in the clinical decision making process so as to enhance the effectiveness and efficiency of extracting value from the associated spend in order to optimize outcomes.
Pursuant to the above, and in response to an unmet need in the marketplace, the VBCC developed a short form in order to enhance the effectiveness and efficiency with which value propositions can be shared between industry and the medical leadership of various payers throughout the country. This same short form provides a concise and consistent manner with which value propositions can be shared and provides the ability to align expectations prior to actually conducting conversations or having a meeting regarding a product or service.
The Product Value Proposition Customer Engagement Short Form can be found on the NAMCP website (www.namcp.org) in the Value Based Care Council subsection of the Councils tab, under tools and resources. Please contact Will Williams at wwilliams@namcp.org with questions or for additional information.
|
| Jazz Pharmaceuticals is excited to announce the approval of ZEPZELCA™ (lurbinectedin) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. ZEPZELCA is a second-line therapy that has been studied in both platinum-sensitive and -resistant SCLC patients. Please click here for more information.
|
| Takeda Pharmaceuticals is part of, "The Fight Is In Us", an initiative to maximize the individual and societal benefit of COVID-19 plasma. The campaign will focus on recruiting COVID-19 survivors to donate their plasma at licensed blood and plasma donor centers.- If you’ve recovered from #COVID19, your immune system has antibodies that could be used as a treatment. See if you can help others by donating plasma www.TheFightIsInUs.org. #TheFightIsInUS
- The antibodies that helped you or someone you know fight off COVID-19 may be able to help others. Visit www.TheFightIsInUs.org to see if you qualify to donate plasma. #TheFightIsInUs
You are a survivor, now you could be a hero. Plasma from recovered #COVID19 patients could play a key role in creating a potential therapy for coronavirus. Learn how you can donate at www.TheFightIsInUs.org #TheFightIsInUs
|
| Biodesix, Inc., a leading diagnostic company in lung disease, recently announced a partnership with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) to bring a COVID-19 Droplet Digital PCR (ddPCR) test to the FDA for an Emergency Use Authorization (EUA) approval to support the escalating need for testing in the U.S. Two studies published this month, ahead of peer review, reported that ddPCR testing showed superior sensitivity and precision for clinical detection of SARS-CoV-2 (the virus that causes COVID-19) compared to existing test methods that are performed using qPCR. Biodesix currently has a focus on lung disease and offers other diagnostic testing for lung cancer utilizing the ddPCR platform.Click here for more information.
|
| "Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attack" was recently published in the Journal of Managed Care Pharmacy's February 2020 issue. Hereditary angioedema (HAE) is a rare disease that causes painful and potentially fatal episodes of swelling (attacks). HAE attacks can be unpredictable and the need to treat sudden attacks promptly and effectively is critical to minimize risk of hospitalization, morbidity, and mortality. A cost-effectiveness model was evaluated that considers evaluation of on-demand medications, healthcare utilization and patient well-being. For access to the publication, please click here.
|
| Biodesix, Inc. announced initiation of the next phase of their biomarker development program with Merck KGaA, Darmstadt, Germany and Pfizer Inc. The companies have completed initial discovery and development of a new proteomic test that identifies likely responders to the anti-PD-L1 checkpoint inhibitor (BAVENCIO®) (avelumab). Development efforts will now focus on transferring the test into Biodesix's CLIA lab in Boulder, CO for clinical phase test validation. The new test was developed through retrospective analysis of the circulating proteome of cancer patients treated with the investigational drug candidate, utilizing the proprietary Biodesix Diagnostic Cortex™ artificial intelligence (AI) platform. Click here to read the full press release.
|
| The NAMCP Medical Directors Institute recently held the first meeting of its Executive Leadership Council (ELC) at the recent Fall Managed Care Forum. The NAMCP Medical Directors Institute decided in late 2018 to create the Value Based Care Council (VBCC) with a mission to empower medical directors with information and resources to assist them in making value based decisions that support achieving the Triple AIM of improved outcomes and the patient experience while reducing overall costs. Click here to view an overview of the genesis, formation, and work of NAMCP's Value Based Care Council. Please click here to view the press release.
|
| LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the first patient enrolled in "A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression" (RECOVER). The study will evaluate Vagus Nerve Stimulation Therapy (VNS Therapy) for Treatment-Resistant Depression (TRD) in accordance with the U.S. Centers for Medicare & Medicaid Services (CMS) National Coverage Determination as part of its Coverage with Evidence Development Program. The first patient was enrolled by Dr. Azfar Malik in St. Louis. Click here to read the full press release.
|
| Biodesix, Inc. this week highlighted findings from multiple studies demonstrating the significance and clinical utility of its VeriStrat® blood-based proteomic test as a predictive biomarker for patient survival outcomes and as a diagnostic tool to improve the clinical management of patients with non-small cell lung cancer (NSCLC). This information is vital to implementing optimal treatment strategies for patients and supports disease state monitoring. To date, VeriStrat testing has helped more than 50,000 patients in determining the best treatment for their lung cancer. Click here to see the full press release. | |
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
